Patents by Inventor Alan Whitmarsh

Alan Whitmarsh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • JNK3 modulators and methods of use
    Publication number: 20060035303
    Abstract: The c-Jun NH2-terminal kinase (JNK) group of MAP kinases are activated by exposure of cells to environmental stress. The role of JNK in the brain was examined by targeted disruption of the gene that encodes the neuronal isoform JNK3. It was found that JNK3 is required for the normal response to seizure activity. Methods of screening for molecules and compounds that decrease JNK3 expression or activity are described. Such molecules or compounds are useful for treating disorders involving excitotoxicity such as seizure disorders, Alzheimer's disease, Huntington disease, Parkinson's disease, and ischaemia.
    Type: Application
    Filed: July 12, 2005
    Publication date: February 16, 2006
    Inventors: Roger Davis, Alan Whitmarsh
  • Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
    Patent number: 6610523
    Abstract: Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including cytokines and environmental stress. Methods are provided for identifying reagents that modulate MKK function or activity and for the use of such reagents in the treatment of MKK-mediated disorders.
    Type: Grant
    Filed: June 13, 2000
    Date of Patent: August 26, 2003
    Assignee: University of Massachusetts
    Inventors: Roger J. Davis, Alan Whitmarsh, Cathy Tournier
  • Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
    Publication number: 20030129606
    Abstract: Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including cytokines and environmental stress. Methods are provided for identifying reagents that modulate MKK function or activity and for the use of such reagents in the treatment of MKK-mediated disorders.
    Type: Application
    Filed: May 3, 2002
    Publication date: July 10, 2003
    Applicant: University of Massachusetts, a Massachusetts corporation
    Inventors: Roger J. Davis, Alan Whitmarsh, Cathy Tournier
  • Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
    Patent number: 6136596
    Abstract: Disclosed are human mitogen-activated (MAP) kinase kinase isoforms (MKKs). MKKs mediate unique signal transduction pathways that activate human MAP kinases p38 and JNK, which result in activation of other factors, including activating transcription factor-2 (ATF2) and c-Jun. The pathways are activated by a number of factors, including cytokines and environmental stress. Methods are provided for identifying reagents that modulate MKK function or activity and for the use of such reagents in the treatment of MKK-mediated disorders.
    Type: Grant
    Filed: July 7, 1997
    Date of Patent: October 24, 2000
    Assignee: University of Massachusetts
    Inventors: Roger J. Davis, Alan Whitmarsh, Cathy Tournier